Printed From BioPortfolio.com
EU Follows US and Approves Chugai’s ALK Inhibitor “Alecensa®” as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
02:04 EST 21 Dec 2017 | Biotech 365
– Alecensa Now Available in Japan, the United States and Europe for the Treatment of Advanced Lung Cancer – TOKYO–(BUSINESS WIRE)–#oncology—Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that F. Hoffmann-La Roche Ltd. obtained approval from the European Commission, for Alecensa® … Continue reading
Cet article EU Follows US and Approves Chugai’s ALK Inhibitor “Alecensa®” as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer est apparu en premier sur Biotech 365.
Original Article: EU Follows US and Approves Chugai’s ALK Inhibitor “Alecensa®” as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
